IMDZ Immune Design Corp.

Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that senior management will present at the following upcoming investor conferences:

13th Annual Wells Fargo Securities Healthcare ConferenceWednesday, September 5, 2018 at 1:50 p.m. Eastern Time in Boston.

H.C. Wainwright & Co. 20th Annual Global Investment ConferenceThursday, September 6, 2018 at 10:50 a.m. Eastern Time in New York.

A live webcast of each presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm . After the live webcast, an archive of each presentation will be available on the company website for 30 days.

About Immune Design

Immune Design is a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic immune cells to fight cancer and other chronic diseases.  CMB305 and G100, the leading product candidates with broad potential in oncology, are based on the company’s two technology platforms that are potent stimulators of the immune system: ZVex® and GLAAS®.  Both ZVex and GLAAS also have potential applications in infectious disease and allergy indications, which are being developed through ongoing pharmaceutical collaborations.  Immune Design has offices in Seattle and South San Francisco. For more information, please visit www.immunedesign.com.

Media ContactJulie RathbunRathbun Communicationsjulie@rathbuncomm.com      206-769-9219

Investor ContactSylvia WheelerSylvia.wheeler@immunedesign.com